{"id":"W2610975296","doi":"10.5430/jst.v7n2p28","title":"A phase II trial of neoadjuvant doxorubicin plus cyclophosphamide followed by lapatinib plus docetaxel sequential with adjuvant trastuzumab for treatment of early HER2 positive breast cancers","year":2017,"lang":"en","type":"article","venue":"Journal of Solid Tumors","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Trastuzumab; Lapatinib; Docetaxel; Breast cancer; Internal medicine; Oncology; Pertuzumab; Population; Anemia; Cyclophosphamide; Lumpectomy; Phases of clinical research; Gastroenterology; Surgery; Chemotherapy; Cancer; Mastectomy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001744472,0.001429614,0.001784333,0.0004789864,0.0004211172,0.0008520327,0.0009602074,0.001019339,0.003292618],"category_scores_gemma":[0.001061811,0.0006422753,0.000806756,0.0004031077,0.001139639,0.0008345859,0.0003733418,0.003084356,0.0007036914],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001024587,"about_ca_system_score_gemma":0.002317633,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007697913,"about_ca_topic_score_gemma":0.002458558,"domain_scores_codex":[0.9994956,0.0002592991,0.00003119167,0.00009196795,0.00004590461,0.00007605776],"domain_scores_gemma":[0.9991115,0.0001468045,0.0002084347,0.00007309725,0.00004624046,0.0004139799],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.833791,0.08539118,0.003494741,0.0006177321,0.0007587123,0.0001423075,0.0001529405,0.001525038,0.01892211,0.0001659925,0.001565367,0.05347285],"study_design_scores_gemma":[0.7038011,0.2907665,0.002629862,0.00001897122,0.0001457489,0.000125022,0.00002220947,0.0005048863,0.001301266,0.00006085867,0.0006116563,0.0000119496],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941754,0.001081578,0.0003598153,0.0003538115,0.000149257,0.002522015,0.0003406692,0.00006021599,0.0009572786],"genre_scores_gemma":[0.9889967,0.001374793,0.002223384,0.0006702037,0.0002220777,0.003692089,0.0009964411,0.00001895692,0.001805362],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003292618,"threshold_uncertainty_score":0.01101494,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03530434100853432,"score_gpt":0.3800850140741496,"score_spread":0.3447806730656153,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}